Food manufacturers often add preservatives to food products to keep them fresh. A primary purpose of these preservatives is to kill microbes that could break down and otherwise… read more.
On 14 December 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product… read more.
In a major advancement in medical technology, researchers at the Terasaki Institute for Biomedical Innovation have developed an adhesive gel, offering a revolutionary treatment for gastrointestinal leaks, a… read more.
Phathom Pharmaceuticals, Inc. announced the FDA has approved Voqenza (vonoprazan) tablets 10 mg and 20 mg, a novel potassium-competitive acid blocker (PCAB), as a new treatment for adults… read more.
Researchers at the Francis Crick Institute and Aalborg University in Copenhagen have shown that changes can be detected in blood tests up to eight years before a diagnosis… read more.
University of Queensland researchers have shown that endometriosis and irritable bowel syndrome (IBS) share genetic risk factors, explaining why patients with one condition may also have the other…. read more.
AbbVie will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from October 14-17. AbbVie… read more.
Researchers from the Netherlands conducted a qualitative study to explore parental motivations, expectations, and experiences of off-hours primary care contacts for children with acute gastroenteritis. They conducted 14… read more.
Brigham researchers found that patients prescribed amoxicillin-clavulanate had higher rates of gastrointestinal symptoms and yeast infections than those prescribed amoxicillin Acute sinusitis is one of the most common… read more.
While life expectancy rates for older Americans are rising, nearly 40% of adults report living with a digestive disease of some kind. “Many people don’t realize that these… read more.
AbbVie announced top-line results from the Phase III SEQUENCE clinical trial evaluating risankizumab (Skyrizi, 600 mg intravenous [IV] induction at week 0, 4 and 8 and 360 mg… read more.
Babies and young children with more mature communities of bacteria present in their gut are less likely to develop allergy-related wheezing or asthma, according to research presented at… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
